市場調査レポート
商品コード
1234268

中枢神経系(CNS)刺激薬の世界市場 2023-2027

Global Central Nervous System (CNS) Stimulant Drugs Market 2023-2027

出版日: | 発行: TechNavio | ページ情報: 英文 161 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
中枢神経系(CNS)刺激薬の世界市場 2023-2027
出版日: 2023年02月22日
発行: TechNavio
ページ情報: 英文 161 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、中枢神経系(CNS)刺激薬市場をモニターしており、2022年から2027年の間に64億8,671万米ドルの増加となる見通しで、予測期間中のCAGRは5.8%で成長すると予測しています。

当レポートでは、中枢神経系(CNS)刺激薬市場について、全体的な分析、市場規模と予測、動向、成長促進要因・課題、さらに約25のベンダーを網羅したベンダー分析を行っています。

現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新の分析を提供しています。市場は、中枢神経系疾患の増加、新しい覚せい剤の承認、世界の覚せい剤使用の増加によって牽引されています。

本調査では、今後数年間の中枢神経系(CNS)刺激薬市場の成長を促進する主要な理由の一つとして、新世代の薬剤の取り込みが増加していることを挙げています。また、世界の大麻合法化の要求の高まりや、薬剤の再利用の増加も、市場の大きな需要につながると考えられます。

目次

第1章 エグゼクティブサマリー

  • 市場概要

第2章 市場情勢

  • 市場エコシステム

第3章 市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模 2022
  • 市場の見通し:2022-2027年の予測

第4章 市場規模実績

  • 世界の中枢神経系(CNS)覚醒剤市場2017年-2021年
  • 流通チャネルセグメント分析2017-2021
  • アプリケーションセグメント分析2017-2021
  • 地域セグメント分析2017-2021
  • 国セグメント分析2017-2021

第5章 ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争の脅威
  • 市況

第6章 流通チャネル別市場セグメンテーション

  • 市場セグメント
  • 流通チャネル別比較
  • 病院 - 市場規模と予測 2022-2027
  • その他 - 市場規模と予測 2022-2027
  • 流通チャネル別の市場機会

第7章 アプリケーション別市場セグメンテーション

  • 市場セグメント
  • 用途別比較
  • 注意欠陥・多動性障害 - 市場規模と予測 2022-2027
  • ナルコレプシー - 市場規模と予測 2022-2027
  • その他 - 市場規模と予測 2022-2027
  • アプリケーション別の市場機会

第8章 顧客情勢

  • 顧客情勢の概要

第9章 地域別情勢

  • 地域別セグメンテーション
  • 地域別比較
  • 北米 - 市場規模と予測 2022-2027
  • 欧州 - 市場規模と予測 2022-2027
  • アジア - 市場規模と予測 2022-2027
  • その他の地域(ROW) - 市場規模と予測 2022-2027
  • 米国 - 市場規模と予測 2022-2027
  • カナダ - 市場規模と予測 2022-2027
  • 英国 - 市場規模と予測 2022-2027
  • ドイツ - 市場規模と予測 2022-2027
  • 中国 - 市場規模と予測 2022-2027
  • 地域別の市場機会

第10章 促進要因、課題、および動向

  • 市場促進要因
  • 市場の課題
  • 促進要因と課題の影響
  • 市場動向

第11章 ベンダー情勢

  • 概要
  • ベンダー情勢
  • 混乱の状況
  • 業界のリスク

第12章 ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • Azurity Pharmaceuticals Inc.
  • Elite Pharmaceuticals Inc.
  • Hisamitsu Pharmaceutical Co. Inc.
  • Ironshore
  • Jazz Pharmaceuticals Plc
  • KemPharm Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Purdue Pharma LP
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Tris Pharma Inc.
  • Viatris Inc.

第13章 付録

図表

Exhibits:

  • Exhibits1: Executive Summary - Chart on Market Overview
  • Exhibits2: Executive Summary - Data Table on Market Overview
  • Exhibits3: Executive Summary - Chart on Global Market Characteristics
  • Exhibits4: Executive Summary - Chart on Market by Geography
  • Exhibits5: Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Exhibits6: Executive Summary - Chart on Market Segmentation by Application
  • Exhibits7: Executive Summary - Chart on Incremental Growth
  • Exhibits8: Executive Summary - Data Table on Incremental Growth
  • Exhibits9: Executive Summary - Chart on Vendor Market Positioning
  • Exhibits10: Parent market
  • Exhibits11: Market Characteristics
  • Exhibits12: Offerings of vendors included in the market definition
  • Exhibits13: Market segments
  • Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibits18: Historic Market Size - Data Table on Global central nervous system (CNS) stimulant drugs market 2017 - 2021 ($ million)
  • Exhibits19: Historic Market Size - Distribution channel Segment 2017 - 2021 ($ million)
  • Exhibits20: Historic Market Size - Application Segment 2017 - 2021 ($ million)
  • Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
  • Exhibits23: Five forces analysis - Comparison between 2022 and 2027
  • Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • Exhibits29: Chart on Market condition - Five forces 2022 and 2027
  • Exhibits30: Chart on Distribution Channel - Market share 2022-2027 (%)
  • Exhibits31: Data Table on Distribution Channel - Market share 2022-2027 (%)
  • Exhibits32: Chart on Comparison by Distribution Channel
  • Exhibits33: Data Table on Comparison by Distribution Channel
  • Exhibits34: Chart on Hospitals - Market size and forecast 2022-2027 ($ million)
  • Exhibits35: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million)
  • Exhibits36: Chart on Hospitals - Year-over-year growth 2022-2027 (%)
  • Exhibits37: Data Table on Hospitals - Year-over-year growth 2022-2027 (%)
  • Exhibits38: Chart on Others - Market size and forecast 2022-2027 ($ million)
  • Exhibits39: Data Table on Others - Market size and forecast 2022-2027 ($ million)
  • Exhibits40: Chart on Others - Year-over-year growth 2022-2027 (%)
  • Exhibits41: Data Table on Others - Year-over-year growth 2022-2027 (%)
  • Exhibits42: Market opportunity by Distribution Channel ($ million)
  • Exhibits43: Data Table on Market opportunity by Distribution Channel ($ million)
  • Exhibits44: Chart on Application - Market share 2022-2027 (%)
  • Exhibits45: Data Table on Application - Market share 2022-2027 (%)
  • Exhibits46: Chart on Comparison by Application
  • Exhibits47: Data Table on Comparison by Application
  • Exhibits48: Chart on Attention-deficit hyperactivity disorder - Market size and forecast 2022-2027 ($ million)
  • Exhibits49: Data Table on Attention-deficit hyperactivity disorder - Market size and forecast 2022-2027 ($ million)
  • Exhibits50: Chart on Attention-deficit hyperactivity disorder - Year-over-year growth 2022-2027 (%)
  • Exhibits51: Data Table on Attention-deficit hyperactivity disorder - Year-over-year growth 2022-2027 (%)
  • Exhibits52: Chart on Narcolepsy - Market size and forecast 2022-2027 ($ million)
  • Exhibits53: Data Table on Narcolepsy - Market size and forecast 2022-2027 ($ million)
  • Exhibits54: Chart on Narcolepsy - Year-over-year growth 2022-2027 (%)
  • Exhibits55: Data Table on Narcolepsy - Year-over-year growth 2022-2027 (%)
  • Exhibits56: Chart on Others - Market size and forecast 2022-2027 ($ million)
  • Exhibits57: Data Table on Others - Market size and forecast 2022-2027 ($ million)
  • Exhibits58: Chart on Others - Year-over-year growth 2022-2027 (%)
  • Exhibits59: Data Table on Others - Year-over-year growth 2022-2027 (%)
  • Exhibits60: Market opportunity by Application ($ million)
  • Exhibits61: Data Table on Market opportunity by Application ($ million)
  • Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Exhibits63: Chart on Market share by geography 2022-2027 (%)
  • Exhibits64: Data Table on Market share by geography 2022-2027 (%)
  • Exhibits65: Chart on Geographic comparison
  • Exhibits66: Data Table on Geographic comparison
  • Exhibits67: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibits69: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits70: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • Exhibits71: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits72: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibits73: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits74: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibits75: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits76: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibits77: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits78: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibits79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibits81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibits83: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits84: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibits85: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibits86: Data Table on US - Year-over-year growth 2022-2027 (%)
  • Exhibits87: Chart on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibits88: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibits89: Chart on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibits90: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibits91: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibits92: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibits93: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibits94: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • Exhibits95: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibits96: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibits97: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibits98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibits99: Chart on China - Market size and forecast 2022-2027 ($ million)
  • Exhibits100: Data Table on China - Market size and forecast 2022-2027 ($ million)
  • Exhibits101: Chart on China - Year-over-year growth 2022-2027 (%)
  • Exhibits102: Data Table on China - Year-over-year growth 2022-2027 (%)
  • Exhibits103: Market opportunity by geography ($ million)
  • Exhibits104: Data Tables on Market opportunity by geography ($ million)
  • Exhibits105: Impact of drivers and challenges in 2022 and 2027
  • Exhibits106: Overview on Criticality of inputs and Factors of differentiation
  • Exhibits107: Overview on factors of disruption
  • Exhibits108: Impact of key risks on business
  • Exhibits109: Vendors covered
  • Exhibits110: Matrix on vendor position and classification
  • Exhibits111: Azurity Pharmaceuticals Inc. - Overview
  • Exhibits112: Azurity Pharmaceuticals Inc. - Product / Service
  • Exhibits113: Azurity Pharmaceuticals Inc. - Key offerings
  • Exhibits114: Elite Pharmaceuticals Inc. - Overview
  • Exhibits115: Elite Pharmaceuticals Inc. - Business segments
  • Exhibits116: Elite Pharmaceuticals Inc. - Key offerings
  • Exhibits117: Elite Pharmaceuticals Inc. - Segment focus
  • Exhibits118: Hisamitsu Pharmaceutical Co. Inc. - Overview
  • Exhibits119: Hisamitsu Pharmaceutical Co. Inc. - Product / Service
  • Exhibits120: Hisamitsu Pharmaceutical Co. Inc. - Key offerings
  • Exhibits121: Ironshore - Overview
  • Exhibits122: Ironshore - Product / Service
  • Exhibits123: Ironshore - Key offerings
  • Exhibits124: Jazz Pharmaceuticals Plc - Overview
  • Exhibits125: Jazz Pharmaceuticals Plc - Product / Service
  • Exhibits126: Jazz Pharmaceuticals Plc - Key news
  • Exhibits127: Jazz Pharmaceuticals Plc - Key offerings
  • Exhibits128: KemPharm Inc. - Overview
  • Exhibits129: KemPharm Inc. - Product / Service
  • Exhibits130: KemPharm Inc. - Key offerings
  • Exhibits131: Merck and Co. Inc. - Overview
  • Exhibits132: Merck and Co. Inc. - Business segments
  • Exhibits133: Merck and Co. Inc. - Key news
  • Exhibits134: Merck and Co. Inc. - Key offerings
  • Exhibits135: Merck and Co. Inc. - Segment focus
  • Exhibits136: Novartis AG - Overview
  • Exhibits137: Novartis AG - Business segments
  • Exhibits138: Novartis AG - Key offerings
  • Exhibits139: Novartis AG - Segment focus
  • Exhibits140: Pfizer Inc. - Overview
  • Exhibits141: Pfizer Inc. - Product / Service
  • Exhibits142: Pfizer Inc. - Key news
  • Exhibits143: Pfizer Inc. - Key offerings
  • Exhibits144: Purdue Pharma LP - Overview
  • Exhibits145: Purdue Pharma LP - Product / Service
  • Exhibits146: Purdue Pharma LP - Key offerings
  • Exhibits147: Sanofi SA - Overview
  • Exhibits148: Sanofi SA - Business segments
  • Exhibits149: Sanofi SA - Key news
  • Exhibits150: Sanofi SA - Key offerings
  • Exhibits151: Sanofi SA - Segment focus
  • Exhibits152: Takeda Pharmaceutical Co. Ltd. - Overview
  • Exhibits153: Takeda Pharmaceutical Co. Ltd. - Product / Service
  • Exhibits154: Takeda Pharmaceutical Co. Ltd. - Key news
  • Exhibits155: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • Exhibits156: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibits157: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibits158: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibits159: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibits160: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibits161: Tris Pharma Inc. - Overview
  • Exhibits162: Tris Pharma Inc. - Product / Service
  • Exhibits163: Tris Pharma Inc. - Key offerings
  • Exhibits164: Viatris Inc. - Overview
  • Exhibits165: Viatris Inc. - Business segments
  • Exhibits166: Viatris Inc. - Key offerings
  • Exhibits167: Viatris Inc. - Segment focus
  • Exhibits168: Inclusions checklist
  • Exhibits169: Exclusions checklist
  • Exhibits170: Currency conversion rates for US$
  • Exhibits171: Research methodology
  • Exhibits172: Validation techniques employed for market sizing
  • Exhibits173: Information sources
  • Exhibits174: List of abbreviations
目次
Product Code: IRTNTR72695

Technavio has been monitoring the central nervous system (CNS) stimulant drugs market and is forecast to grow by $6486.71 mn during 2022-2027, accelerating at a CAGR of 5.8% during the forecast period. Our report on the central nervous system (CNS) stimulant drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rise in CNS disorders, approval of new stimulants, and increasing use of stimulants worldwide.

Technavio's central nervous system (CNS) stimulant drugs market is segmented as below:

By Distribution Channel

  • Hospitals
  • Others

By Application

  • Attention-deficit hyperactivity disorder
  • Narcolepsy
  • Others

By Geography

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)

This study identifies the increased uptake of new-generation drugs as one of the prime reasons driving the central nervous system (CNS) stimulant drugs market growth during the next few years. Also, rising demand to legalize cannabis worldwide and increasing repurposing of drugs will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the central nervous system (CNS) stimulant drugs market covers the following areas:

  • Central nervous system (CNS) stimulant drugs market sizing
  • Central nervous system (CNS) stimulant drugs market forecast
  • Central nervous system (CNS) stimulant drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading central nervous system (CNS) stimulant drugs market vendors that include Astellas Pharma Inc., Azurity Pharmaceuticals Inc., Elite Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Ironshore, Jazz Pharmaceuticals Plc, KemPharm Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Purdue Pharma LP, Sanofi SA, Shionogi and Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tris Pharma Inc., Viatris Inc., and Thermo Fisher Scientific Inc. Also, the central nervous system (CNS) stimulant drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
  • Exhibit 01: Executive Summary - Chart on Market Overview
  • Exhibit 02: Executive Summary - Data Table on Market Overview
  • Exhibit 03: Executive Summary - Chart on Global Market Characteristics
  • Exhibit 04: Executive Summary - Chart on Market by Geography
  • Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Exhibit 06: Executive Summary - Chart on Market Segmentation by Application
  • Exhibit 07: Executive Summary - Chart on Incremental Growth
  • Exhibit 08: Executive Summary - Data Table on Incremental Growth
  • Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 10: Parent market
  • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
  • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027
  • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
  • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
  • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global central nervous system (CNS) stimulant drugs market 2017 - 2021
  • Exhibit 18: Historic Market Size - Data Table on Global central nervous system (CNS) stimulant drugs market 2017 - 2021 ($ million)
  • 4.2 Distribution channel Segment Analysis 2017 - 2021
  • Exhibit 19: Historic Market Size - Distribution channel Segment 2017 - 2021 ($ million)
  • 4.3 Application Segment Analysis 2017 - 2021
  • Exhibit 20: Historic Market Size - Application Segment 2017 - 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 - 2021
  • Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 - 2021
  • Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
  • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
  • 5.2 Bargaining power of buyers
  • Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers
  • Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants
  • Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes
  • Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry
  • Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
  • 5.7 Market condition
  • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Distribution Channel

  • 6.1 Market segments
  • Exhibit 30: Chart on Distribution Channel - Market share 2022-2027 (%)
  • Exhibit 31: Data Table on Distribution Channel - Market share 2022-2027 (%)
  • 6.2 Comparison by Distribution Channel
  • Exhibit 32: Chart on Comparison by Distribution Channel
  • Exhibit 33: Data Table on Comparison by Distribution Channel
  • 6.3 Hospitals - Market size and forecast 2022-2027
  • Exhibit 34: Chart on Hospitals - Market size and forecast 2022-2027 ($ million)
  • Exhibit 35: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million)
  • Exhibit 36: Chart on Hospitals - Year-over-year growth 2022-2027 (%)
  • Exhibit 37: Data Table on Hospitals - Year-over-year growth 2022-2027 (%)
  • 6.4 Others - Market size and forecast 2022-2027
  • Exhibit 38: Chart on Others - Market size and forecast 2022-2027 ($ million)
  • Exhibit 39: Data Table on Others - Market size and forecast 2022-2027 ($ million)
  • Exhibit 40: Chart on Others - Year-over-year growth 2022-2027 (%)
  • Exhibit 41: Data Table on Others - Year-over-year growth 2022-2027 (%)
  • 6.5 Market opportunity by Distribution Channel
  • Exhibit 42: Market opportunity by Distribution Channel ($ million)
  • Exhibit 43: Data Table on Market opportunity by Distribution Channel ($ million)

7 Market Segmentation by Application

  • 7.1 Market segments
  • Exhibit 44: Chart on Application - Market share 2022-2027 (%)
  • Exhibit 45: Data Table on Application - Market share 2022-2027 (%)
  • 7.2 Comparison by Application
  • Exhibit 46: Chart on Comparison by Application
  • Exhibit 47: Data Table on Comparison by Application
  • 7.3 Attention-deficit hyperactivity disorder - Market size and forecast 2022-2027
  • Exhibit 48: Chart on Attention-deficit hyperactivity disorder - Market size and forecast 2022-2027 ($ million)
  • Exhibit 49: Data Table on Attention-deficit hyperactivity disorder - Market size and forecast 2022-2027 ($ million)
  • Exhibit 50: Chart on Attention-deficit hyperactivity disorder - Year-over-year growth 2022-2027 (%)
  • Exhibit 51: Data Table on Attention-deficit hyperactivity disorder - Year-over-year growth 2022-2027 (%)
  • 7.4 Narcolepsy - Market size and forecast 2022-2027
  • Exhibit 52: Chart on Narcolepsy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 53: Data Table on Narcolepsy - Market size and forecast 2022-2027 ($ million)
  • Exhibit 54: Chart on Narcolepsy - Year-over-year growth 2022-2027 (%)
  • Exhibit 55: Data Table on Narcolepsy - Year-over-year growth 2022-2027 (%)
  • 7.5 Others - Market size and forecast 2022-2027
  • Exhibit 56: Chart on Others - Market size and forecast 2022-2027 ($ million)
  • Exhibit 57: Data Table on Others - Market size and forecast 2022-2027 ($ million)
  • Exhibit 58: Chart on Others - Year-over-year growth 2022-2027 (%)
  • Exhibit 59: Data Table on Others - Year-over-year growth 2022-2027 (%)
  • 7.6 Market opportunity by Application
  • Exhibit 60: Market opportunity by Application ($ million)
  • Exhibit 61: Data Table on Market opportunity by Application ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview
  • Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation
  • Exhibit 63: Chart on Market share by geography 2022-2027 (%)
  • Exhibit 64: Data Table on Market share by geography 2022-2027 (%)
  • 9.2 Geographic comparison
  • Exhibit 65: Chart on Geographic comparison
  • Exhibit 66: Data Table on Geographic comparison
  • 9.3 North America - Market size and forecast 2022-2027
  • Exhibit 67: Chart on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 68: Data Table on North America - Market size and forecast 2022-2027 ($ million)
  • Exhibit 69: Chart on North America - Year-over-year growth 2022-2027 (%)
  • Exhibit 70: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • 9.4 Europe - Market size and forecast 2022-2027
  • Exhibit 71: Chart on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 72: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
  • Exhibit 73: Chart on Europe - Year-over-year growth 2022-2027 (%)
  • Exhibit 74: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • 9.5 Asia - Market size and forecast 2022-2027
  • Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
  • Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%)
  • Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
  • Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
  • Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • 9.7 US - Market size and forecast 2022-2027
  • Exhibit 83: Chart on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 84: Data Table on US - Market size and forecast 2022-2027 ($ million)
  • Exhibit 85: Chart on US - Year-over-year growth 2022-2027 (%)
  • Exhibit 86: Data Table on US - Year-over-year growth 2022-2027 (%)
  • 9.8 Canada - Market size and forecast 2022-2027
  • Exhibit 87: Chart on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 88: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
  • Exhibit 89: Chart on Canada - Year-over-year growth 2022-2027 (%)
  • Exhibit 90: Data Table on Canada - Year-over-year growth 2022-2027 (%)
  • 9.9 UK - Market size and forecast 2022-2027
  • Exhibit 91: Chart on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 92: Data Table on UK - Market size and forecast 2022-2027 ($ million)
  • Exhibit 93: Chart on UK - Year-over-year growth 2022-2027 (%)
  • Exhibit 94: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • 9.10 Germany - Market size and forecast 2022-2027
  • Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
  • Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
  • Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • 9.11 China - Market size and forecast 2022-2027
  • Exhibit 99: Chart on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 100: Data Table on China - Market size and forecast 2022-2027 ($ million)
  • Exhibit 101: Chart on China - Year-over-year growth 2022-2027 (%)
  • Exhibit 102: Data Table on China - Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity by geography
  • Exhibit 103: Market opportunity by geography ($ million)
  • Exhibit 104: Data Tables on Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges
  • Exhibit 105: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape
  • Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption
  • Exhibit 107: Overview on factors of disruption
  • 11.4 Industry risks
  • Exhibit 108: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered
  • Exhibit 109: Vendors covered
  • 12.2 Market positioning of vendors
  • Exhibit 110: Matrix on vendor position and classification
  • 12.3 Azurity Pharmaceuticals Inc.
  • Exhibit 111: Azurity Pharmaceuticals Inc. - Overview
  • Exhibit 112: Azurity Pharmaceuticals Inc. - Product / Service
  • Exhibit 113: Azurity Pharmaceuticals Inc. - Key offerings
  • 12.4 Elite Pharmaceuticals Inc.
  • Exhibit 114: Elite Pharmaceuticals Inc. - Overview
  • Exhibit 115: Elite Pharmaceuticals Inc. - Business segments
  • Exhibit 116: Elite Pharmaceuticals Inc. - Key offerings
  • Exhibit 117: Elite Pharmaceuticals Inc. - Segment focus
  • 12.5 Hisamitsu Pharmaceutical Co. Inc.
  • Exhibit 118: Hisamitsu Pharmaceutical Co. Inc. - Overview
  • Exhibit 119: Hisamitsu Pharmaceutical Co. Inc. - Product / Service
  • Exhibit 120: Hisamitsu Pharmaceutical Co. Inc. - Key offerings
  • 12.6 Ironshore
  • Exhibit 121: Ironshore - Overview
  • Exhibit 122: Ironshore - Product / Service
  • Exhibit 123: Ironshore - Key offerings
  • 12.7 Jazz Pharmaceuticals Plc
  • Exhibit 124: Jazz Pharmaceuticals Plc - Overview
  • Exhibit 125: Jazz Pharmaceuticals Plc - Product / Service
  • Exhibit 126: Jazz Pharmaceuticals Plc - Key news
  • Exhibit 127: Jazz Pharmaceuticals Plc - Key offerings
  • 12.8 KemPharm Inc.
  • Exhibit 128: KemPharm Inc. - Overview
  • Exhibit 129: KemPharm Inc. - Product / Service
  • Exhibit 130: KemPharm Inc. - Key offerings
  • 12.9 Merck and Co. Inc.
  • Exhibit 131: Merck and Co. Inc. - Overview
  • Exhibit 132: Merck and Co. Inc. - Business segments
  • Exhibit 133: Merck and Co. Inc. - Key news
  • Exhibit 134: Merck and Co. Inc. - Key offerings
  • Exhibit 135: Merck and Co. Inc. - Segment focus
  • 12.10 Novartis AG
  • Exhibit 136: Novartis AG - Overview
  • Exhibit 137: Novartis AG - Business segments
  • Exhibit 138: Novartis AG - Key offerings
  • Exhibit 139: Novartis AG - Segment focus
  • 12.11 Pfizer Inc.
  • Exhibit 140: Pfizer Inc. - Overview
  • Exhibit 141: Pfizer Inc. - Product / Service
  • Exhibit 142: Pfizer Inc. - Key news
  • Exhibit 143: Pfizer Inc. - Key offerings
  • 12.12 Purdue Pharma LP
  • Exhibit 144: Purdue Pharma LP - Overview
  • Exhibit 145: Purdue Pharma LP - Product / Service
  • Exhibit 146: Purdue Pharma LP - Key offerings
  • 12.13 Sanofi SA
  • Exhibit 147: Sanofi SA - Overview
  • Exhibit 148: Sanofi SA - Business segments
  • Exhibit 149: Sanofi SA - Key news
  • Exhibit 150: Sanofi SA - Key offerings
  • Exhibit 151: Sanofi SA - Segment focus
  • 12.14 Takeda Pharmaceutical Co. Ltd.
  • Exhibit 152: Takeda Pharmaceutical Co. Ltd. - Overview
  • Exhibit 153: Takeda Pharmaceutical Co. Ltd. - Product / Service
  • Exhibit 154: Takeda Pharmaceutical Co. Ltd. - Key news
  • Exhibit 155: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 12.15 Teva Pharmaceutical Industries Ltd.
  • Exhibit 156: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibit 157: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 158: Teva Pharmaceutical Industries Ltd. - Key news
  • Exhibit 159: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 160: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 12.16 Tris Pharma Inc.
  • Exhibit 161: Tris Pharma Inc. - Overview
  • Exhibit 162: Tris Pharma Inc. - Product / Service
  • Exhibit 163: Tris Pharma Inc. - Key offerings
  • 12.17 Viatris Inc.
  • Exhibit 164: Viatris Inc. - Overview
  • Exhibit 165: Viatris Inc. - Business segments
  • Exhibit 166: Viatris Inc. - Key offerings
  • Exhibit 167: Viatris Inc. - Segment focus

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist
  • Exhibit 168: Inclusions checklist
  • Exhibit 169: Exclusions checklist
  • 13.3 Currency conversion rates for US$
  • Exhibit 170: Currency conversion rates for US$
  • 13.4 Research methodology
  • Exhibit 171: Research methodology
  • Exhibit 172: Validation techniques employed for market sizing
  • Exhibit 173: Information sources
  • 13.5 List of abbreviations
  • Exhibit 174: List of abbreviations